MALDI mass spec | GenomeWeb

MALDI mass spec

The mass spectrometry services and instrument firm is working with a Yale pathologist to develop proteomic tests for solid tumors.

Scientists from the University of Victoria, SISCAPA Assay Technologies, and Bruker have demonstrated the use of MALDI mass spectrometry for quantifying levels of the putative prostate cancer marker protein C inhibitor in clinical samples.

EGFR has emerged as a primary area of interest in cancer research, with biopharmaceuticals like Imclone's Erbitux and Amgen's Vectibix targeting the protein, but its multiple isoforms have made it difficult to predict these drugs' effectiveness, said Yale professor Nita Maihle.

A portion of the funding will go toward the purchase of a new MALDI TOF-TOF MS-MS machine from upstart mass spec firm Virgin Instruments, a company founded by Marvin Vestal, the former president of mass spectrometry platform R&D at Applied Biosystems and developer of the first commercial MALDI-TOF mass spec.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.